← Back to Search

PI3K/mTOR Inhibitor

Gedatolisib + Talazoparib for Breast Cancer

Phase 1 & 2

Waitlist Available

Led By Kari Wisinski, MD

Research Sponsored by Kari Wisinski

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Archived tumor tissue available

Subjects with histologically confirmed breast cancer that is advanced

Must not have

Any prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of this investigational regimen

Active infection requiring systemic therapy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 months

Awards & highlights

Summary

This trial is testing a new combination of drugs to treat advanced breast cancer that is negative for HER2 and either triple negative or BRCA1/2 positive.

Who is the study for?

This trial is for adults with advanced HER2 negative breast cancer that's either triple negative or BRCA1/2 positive. Participants must have measurable disease, be able to take oral meds, and not be pregnant or breastfeeding. They should agree to use contraception if necessary and have no major health issues like diabetes, active infections, or a history of certain heart conditions.Check my eligibility

What is being tested?

The study tests the combination of gedatolisib plus talazoparib in treating advanced breast cancer. It aims to find the right dose and assess how effective this combo is against specific types of breast cancer that lack three common receptors (triple-negative) or carry BRCA mutations.See study design

What are the potential side effects?

Potential side effects may include reactions related to gastrointestinal function due to talazoparib absorption issues, liver problems from hepatitis B/C risks, blood disorders such as myelodysplastic syndrome or leukemia, increased risk of infection requiring systemic therapy.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have stored samples of my tumor.

Select...

My breast cancer is confirmed and advanced.

Select...

I do not have cancer that has spread to my brain or spinal cord.

Select...

I am not pregnant or breastfeeding.

Select...

I am willing to use two effective birth control methods.

Select...

I am a man who can father children and will use birth control.

Select...

I have advanced triple negative breast cancer without known BRCA gene mutations.

Select...

I do not have a history of type I diabetes.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I don't have any other cancer that could affect this treatment's safety or results.

Select...

I am currently on medication for an infection.

Select...

I have a history of myelodysplastic syndrome or acute myeloid leukemia.

Select...

I am currently taking warfarin or a similar blood thinner.

Select...

I have no GI conditions that affect medication absorption.

Select...

I have not had major surgery in the last 14 days.

Select...

I do not have a history of severe lung, heart, brain, or uncontrolled medical conditions.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Maximum Tolerated Dose (MTD) of talazoparib in combination with gedatolisib (Phase I)

Objective Response Rate (ORR) (Phase II)

Secondary outcome measures

Clinical Benefit Rate (CBR) at 16 weeks

Duration of Response (DOR)

Overall Survival

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Talazoparib + GedatolisibExperimental Treatment2 Interventions

Talazoparib + Gedatolisib Phase 1: Dose Level -1: Gedatolisib 150mg IV, Days 1,8,15,22; Talazoparib 0.75 mg/orally qd, Days 1-28 Dose Level 1: Gedatolisib 180mg IV, Days 1,8,15,22; Talazoparib 0.75 mg/orally qd, Days 1-28 Dose Level 2: Gedatolisib 180mg IV, Days 1,8,15,22; Talazoparib 1.00 mg/orally qd, Days 1-28 Phase 2: Gedatolisib 180 mg IV on days 1, 8, 15 and 22; Talazoparib 1.00 mg once daily, Days 1-28. Subjects receiving weekly gedatolisib may continue current regimen or may switch to gedatolisib 180 mg IV on days 1, 8, and 15; Talazoparib 1.00 mg once daily, Days 1-28 (3 weeks on/ 1 week off). All changes will be permanent.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Gedatolisib

2018

Completed Phase 1

~160

Talazoparib

2021

Completed Phase 2

~2770

0 / 15Eligibility criteria met

Find a Location

Who is running the clinical trial?

Celcuity IncIndustry Sponsor

7 Previous Clinical Trials

970 Total Patients Enrolled

3 Trials studying Breast Cancer

889 Patients Enrolled for Breast Cancer

Kari WisinskiLead Sponsor

2 Previous Clinical Trials

81 Total Patients Enrolled

Celcuity, Inc.Industry Sponsor

6 Previous Clinical Trials

916 Total Patients Enrolled

3 Trials studying Breast Cancer

889 Patients Enrolled for Breast Cancer

~6 spots leftby Jul 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.